Recombinant Adeno-Associated Virus Vectors Induce Functionally Impaired Transgene Product-Specific CD8+ T Cells in Mice
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors were used in human trials as carriers of vaccines for HIV-1 after encouraging preclinical results. However, the clinical trials yielded disappointing results. Here we demonstrated that in mice, rAAV vectors expressing the gene encoding HIV-1 gag stimulated gag-specific CD8(+) T cells, but these T cells failed to expand after a booster immunization with a replication-defective adenoviral (Ad) vector also expressing gag. We tested rAAV vectors of different serotypes expressing HIV-1 gag for induction of transgene product-specific CD8(+) T cells and found that the immunoinhibitory effect of rAAV priming observed with different AAV serotypes was transgene product specific, was independent of the interval between prime and boost, and extended to boosts with vaccine modalities other than Ad vectors. rAAV vector-induced CD8(+) T cells proliferated poorly, produced low levels of IFN-gamma in response to gag stimulation, and upregulated immunoinhibitory molecules. These T cells did not protect efficiently against challenge with a surrogate pathogen. Finally, we showed that the impaired proliferative capacity of the T cells was caused by persistence of the antigen-encoding rAAV vectors and could be reversed by placing the CD8(+) T cells in an antigen-free environment. Our data suggest that rAAV vectors induce functionally impaired T cells and could dampen the immune response to a natural infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These often induce functionally impaired CD8+ T cells against the transgene product with a reduced cytotoxic and proliferative capacity (50), ultimately undergoing apoptosis (51).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 5×
“CD8+ T cells that are continuously immersed in antigen become exhausted, as attested by loss of proliferation to antigen, secretion of cytokines, target cell lysis (35, 75), and upregulation of PD-1 and other negative costimulators; blockade of the PD-1/ PD-L1/2 pathway through antibodies can restore functionality of…”
BackgroundMethodInfluentialPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · cited 2×
“Groups of mice were immunized with 1011 gc rAAV2/7gag and then treated with 200 μg anti-PD-1 antibody, twice prior to boost and 3 times after boost, 3 days apart, as described previously (36, 50, 51).”
MethodCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., & Sacks, D. L. (2002) · Nature · doi:10.1038/nature01152 · Cited by 1,725
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“We could not detect IFN-γ–producing CD4+ T cells in rAAVgagimmunized mice by ELISpot assays (data not shown), and an impaired memory response has previously been described for CD8+ T cells that are activated without T help (65, 66).”
BackgroundThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528 · cited 1×
“It was shown in the chronic LCMV infection model that blockade of the PD-1/program death–ligand 1 (PD-1/PD-L1) pathway reinstates functionality to exhausted CD8+ T cells (36, 52).”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“Several AAV serotypes have been isolated from primates (16, 17), as well as other animals, and have been vectored and tested as gene delivery vehicles (18).”
BackgroundRequirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460 · cited 1×
“We could not detect IFN-γ–producing CD4+ T cells in rAAVgagimmunized mice by ELISpot assays (data not shown), and an impaired memory response has previously been described for CD8+ T cells that are activated without T help (65, 66).”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Several AAV serotypes have been isolated from primates (16, 17), as well as other animals, and have been vectored and tested as gene delivery vehicles (18).”
BackgroundNatural regulatory T cells in infectious disease
Belkaid, Y., & Rouse, B. T. (2005) · Nature Immunology · doi:10.1038/ni1181 · Cited by 1,035
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“They fail to eliminate the transduced muscle, do not respond to boost vaccination, and upregulate immunoinhibitory molecules such as PD-1.”
BackgroundProgress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Cas9 immunity creates challenges for CRISPR gene editing therapies
Crudele, J. M., & Chamberlain, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05843-9 · Cited by 259
Nanotechnology solutions for mucosal immunization
Chadwick, S., Kriegel, C., & Amiji, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.012 · Cited by 203
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Mild immune responses observed in Luxturna and LHON patients can be attributed to local injection into a compartmentalized environment containing elevated concentrations of immunomodulatory neuropeptides and cytokines [139].”
BackgroundInfluentialVandenberghe, L. H., Xiao, R., Lock, M., Lin, J., Korn, M., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.107 · Cited by 151
“Tetramer staining was performed as described previously (J. Lin et al. , 2007).”
Dion, S., Bourgine, M., Godon, O., Levillayer, F., & Michel, M.-L. (2013) · Journal of Virology · doi:10.1128/jvi.03134-12 · Cited by 132
“This was consistent with previous studies that failed to rescue the AAV transgene-induced CD8 T-cell ability to proliferate or to produce cytokines (40).”
MethodResultThe Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 125
Ploquin, A., Szécsi, J., Mathieu, C., Guillaume, V., Barateau, V., Ong, K. C., Wong, K. T., Cosset, F., Horvat, B., & Salvetti, A. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis699 · Cited by 117
“It is possible that a booster effect could be observed only if boosting is performed at a later time, when the humoral response induced by the priming injection has declined.”
BackgroundAAV Vectors Vaccines Against Infectious Diseases
Nieto, K., & Salvetti, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00005 · Cited by 100
Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., & Wilson, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803965 · Cited by 99
“nLacZ elicits virtually no immune response to either nLacZ or the capsid, consistent with previous reports of aberrant T cell responses in mice (40, 41, 43).”
BackgroundResultInfluentialImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
“Early studies in mice showed that IM injection of AAV vectors induced functionally impaired CD8 T cells.(94,95) In wild-type C57BL/6 mice, the risk of a FIX antibody response was dependent on the dose and route of vector administration with IM delivery shown to be substantially more immunogenic compared to intraportal…”
BackgroundAAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Salmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
Cao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., & Herzog, R. W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.159 · Cited by 92
Self-citationOhshima, S., Shin, J.-H., Yuasa, K., Nishiyama, A., Kira, J., Okada, T., & Takeda, S. (2009) · Molecular Therapy · doi:10.1038/mt.2008.225 · Cited by 92
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Self-citationKumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
McIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70
The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
“vector and the antigenic transgene products [71,75–78].”
BackgroundAn efficient method of directly cloning chimpanzee adenovirus as a vaccine vector
Zhou, D., Zhou, X., Bian, A., Li, H., Chen, H., Small, J. C., Li, Y., Giles‐Davis, W., Xiang, Z., & Ertl, H. C. J. (2010) · Nature Protocols · doi:10.1038/nprot.2010.134 · Cited by 68
Self-citationWu, T., Töpfer, K., Lin, S.-W., Li, H., Bian, A., Zhou, X. Y., High, K. A., & Ertl, H. C. (2012) · Molecular Therapy · doi:10.1038/mt.2011.280 · Cited by 66
Self-citationSafety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Haurigot, V., Mingozzi, F., Buchlis, G., Hui, D. J., Chen, Y., Basner-Tschakarjan, E., Arruda, V. R., Radu, A., Franck, H. G., Wright, J. F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.73 · Cited by 66
A New Genetic Vaccine Platform Based on an Adeno-Associated Virus Isolated from a Rhesus Macaque
Lin, J., Calcedo, R., Vandenberghe, L. H., Bell, P., Somanathan, S., & Wilson, J. M. (2009) · Journal of Virology · doi:10.1128/jvi.01441-09 · Cited by 66
Mays, L. E., Wang, L., Lin, J., Bell, P., Crawford, A., Wherry, E. J., & Wilson, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2013.134 · Cited by 62
High, K. A., & Aubourg, P. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_18 · Cited by 60
Viral vectors as vaccine carriers
Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 65
Self-citationImmune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Self-citationBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Yu, H., Fischer, G., Ferhatovic, L., Fan, F., Light, A. R., Weihrauch, D., Sapunar, D., Nakai, H., Park, F., & Hogan, Q. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061266 · Cited by 50
Velazquez, V. M., Bowen, D. G., & Walker, C. M. (2009) · Blood · doi:10.1182/blood-2008-01-131375 · Cited by 46
Nieto, K., Stahl-Hennig, C., Leuchs, B., Müller, M., Gissmann, L., & Kleinschmidt, J. A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.202 · Cited by 46
“A possible disadvantage of such a depot function is T-cell exhaustion, which has been observed for rAAV2 vectors ( J. Lin et al., 2007; S.W. Lin et al., 2007).”
BackgroundRogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
Self-citationRegulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
Gernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
Breous, E., Somanathan, S., Bell, P., & Wilson, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.002 · Cited by 40
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
Nayak, S., Sarkar, D., Perrin, G. Q., Moghimi, B., Hoffman, B. E., Zhou, S., Byrne, B. J., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00244 · Cited by 40
“However, these infiltrating CD8+ T cells are not fully functional and fail to eliminate hFIX-expressing muscle fibers (Wang et al., 2005; Lin et al., 2007; Velazquez et al., 2009).”
BackgroundDelivery strategies to enhance mucosal vaccination
Chadwick, S., Kriegel, C., & Amiji, M. M. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902849224 · Cited by 42
“The use of recombinant adeno-associated virus vectors has been evaluated with varying degrees of success, as some studies have shown them to induce functionally impaired T cells that could reduce the normal immune system response [35].”
BackgroundUnderstanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Yu, S., Feng, X., Shu, T., Matano, T., Hasegawa, M., Wang, X., Ma, H., Li, H., Li, Z., & Zeng, Y. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.017 · Cited by 33
Sipo, I., Knauf, M., Fechner, H., Poller, W. C., Planz, O., Kurth, R., & Norley, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.12.037 · Cited by 38
STEP trial and HIV-1 vaccines inducing T-cell responses
Hanke, T. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.3.303 · Cited by 32
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
Li, H., Tuyishime, S., Wu, T.-L., Giles-Davis, W., Zhou, D., Xiao, W., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.267 · Cited by 30
Self-citationTumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model
Krotova, K. Y., Kuoch, H., Caine, C., & Aslanidi, G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.01.006 · Cited by 31
“An early report that analyzed transgene-specific CD8 T cells primed with an AAV vaccine found that vaccines based on AAV serotypes 1, 2, 5, 7, 8, and 9 induced partially dysfunctional CTLs against transgenes.(2) These CTLs were not able to expand or produce IFNg in response to restimulation and did not protect against…”
BackgroundMuscle‐directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors
Wang, L., Louboutin, J. P., Bell, P. L., Greig, J. A., LI, Y., WU, D., & Wilson, J. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04491.x · Cited by 33
Carpentier, M., Lorain, S., Chappert, P., Lalfer, M., Hardet, R., Urbain, D., Peccate, C., Adriouch, S., Garcia, L., Davoust, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.235 · Cited by 25
Li, X., Cao, H., Wang, Q., Di, B., Wang, M., Lu, J., Pan, L., Yang, L., Mei, M., Pan, X., et al. (2012) · Microbes and Infection · doi:10.1016/j.micinf.2012.05.002 · Cited by 26
Adriouch, S., Franck, E., Drouot, L., Bonneau, C., Jolinon, N., Salvetti, A., & Boyer, O. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00199 · Cited by 22
“It has been argued that the priming of T cells directed to the transgene product may be somehow defective after rAAVmediated gene transfer (Lin et al., 2007a,b).”
BackgroundDeng, Y. L., Zhang, K., Tan, W., Wang, Y., Chen, H., Wu, X., & Ruan, L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.003 · Cited by 22
“Compared to rTTV-E1E2 boosting, rAAV-E1E2 elicited a much lower T-cell response, which was consistent with the recent reports that AAV may impair the T-cell response in certain situations [23] .”
ResultZhu, F., Wang, Y., Xu, Z., Qu, H., Zhang, H., Niu, L., Xue, H., Jing, D., & He, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9739 · Cited by 22
“Such prominent antibody response may be relevant to the high and sustained expression of the immunogen by most AAV serotypes (27-29).”
BackgroundPreclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Self-citationObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine
Haut, L. H., & Ertl, H. C. J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209094 · Cited by 20
Self-citationEvasion of Pre-Existing Immunity to Cas9: A Prerequisite for Successful Genome Editing In Vivo?
Wignakumar, T., & Fairchild, P. J. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-00237-2 · Cited by 19
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
“A lot of studies have demonstrated that no human dystrophin-specific CTL response was elicited in mdx mice after direct intra-muscular injection of AAV vectors, and Treg or anergy/exhausted T lymphocyte can be induced after intramuscular injection of AAV vectors (60,61).”
BackgroundAdenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1
Xie, Z., Ji, Z., Zhang, Z., Gong, T., & Sun, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.056 · Cited by 19
Ahangarani, R. R., Janssens, W., Carlier, V. A., VanderElst, L., VandenDriessche, T., Chuah, M., Jacquemin, M. G., & Saint‐Remy, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.275 · Cited by 19
Xu, D., & Walker, C. M. (2011) · Journal of Virology · doi:10.1128/jvi.05375-11 · Cited by 14
“CD8 T cells targeting these proteins are maintained at low frequencies in the spleens and draining lymph nodes of mice (8, 9) but continuously infiltrate transduced muscle, where they undergo programmed death (14).”
BackgroundHou, Y., Li, Y., Zhang, Y., Zhang, J., & Wu, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1423212 · Cited by 14
Zinkernagel, M. S., McMenamin, P. G., Forrester, J. V., & Degli‐Esposti, M. A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.04.001 · Cited by 11
Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Jordan, I., Lohr, V., Genzel, Y., Reichl, U., & Sandig, V. (2013) · Microorganisms · doi:10.3390/microorganisms1010100 · Cited by 9
“Gene therapy vectors that are designed to maintain prolonged expression of transgenes with minimum damage to the host cell may not be suitable as vaccine vectors if they induce immune tolerance [13,14].”
BackgroundLogan, G. J., Wang, L., Zheng, M., Coppel, R. L., & Alexander, I. E. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.92 · Cited by 8
Ghenassia, A., Gross, D., Lorain, S., Tros, F., Urbain, D., Benkhelifa‐Ziyyat, S., Charbit, A., Davoust, J. M., & Chappert, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.019 · Cited by 9
“For each experiment, organs from n = 3 immunized mice per group were MHC class I upregulation on myocytes(16) and sustained transgene expression,(7,16) or transgene-intrinsic limitations, lack of potent MHC class II epitope in the construct.(7,8) Our results suggest that a combination of signals might be needed.”
BackgroundResultWashburn, M. L., Kovalev, G. I., Koroleva, E. P., Fu, Y., & Su, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010585 · Cited by 6
Autoimmunity, Recessive Diseases, and Gene Replacement Therapy
Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.253 · Cited by 6
Journou, M., Devaux, M., Jaulin, N., Pichard, V., Segovia, M., Moreau, A., Duff, J. L., Cuturi, M. C., Guilbaud, M., & Adjali, O. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101409 · Cited by 8
Merck's HIV vaccine flop brings vectors under closer scrutiny
Ledford, H. K. (2008) · Nature Biotechnology · doi:10.1038/nbt0108-3 · Cited by 5
On the Growing Complexity of HIV-1 Vaccines
Hanke, T. (2010) · HIV Therapy · doi:10.2217/hiv.10.40 · Cited by 4
Teaching an old vector new tricks: the surprising versatility of AAV vaccines
Winston, S. M., Wiggins, K., Schultz‐Cherry, S., & Davidoff, A. M. (2025) · Journal of Virology · doi:10.1128/jvi.00730-25 · Cited by 4
“Although this approach enhances the efficacy of anti-cancer vaccines, prolonged expression of HIV antigens by AAV vectors is believed to be associated with T-cell dysfunction (62).”
Safety of Adeno-Associated Viral Vectors
Lin, S., & Ertl, H. C. J. (2008) · Future Virology · doi:10.2217/17460794.3.5.491 · Cited by 3
“However, the gag-specific CD8+ T-cell response was impaired in that there was a reduced capacity for cytokine release, lysis or proliferation upon antigen re-exposure [132].”
BackgroundSelf-citationHIV Immunology and Prospects for Vaccines
Jülg, B. D., & Walker, B. D. (2009) · doi:10.1002/9783527627905.ch1 · Cited by 2
Ashley, S. N., Somanathan, S., Hinderer, C. J., Arias, M., McMenamin, D., Draper, C., & Wilson, J. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601131 · Cited by 1
“Previous research has shown that peripheral tolerance to a foreign protein or epitope can be achieved by expressing it in the liver using an AAV vector (41).”
BackgroundSafroneeva, E. (2009) · MacSphere (McMaster University) · doi:10.71548/10686
Modulating Immune Responses in Muscle Gene Therapy
Arruda, V. R. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_11
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
“between tissue being targeted, namely the skeletal muscle in previous studies (7, 8), and”
BackgroundInfluentialChand, A. (2012) · Mspace (University of Manitoba)
Modeling HCV infection, immunopathogenesis, and therapy in humanized mice
Washburn, M. L. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/zed0-re37
Ertl, H. C. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29979-7.00013-1
Self-citationEtude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Jeanpierre, L., Pecquet, C., Saliba, H., Finard, P., Terry, S., Tavella, G., Guesmia, I., Boutin, S., Bertin, B., Benkhelifa‐Ziyyat, S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202541
“Previous studies reported dysfunctional CD8 + response following intramuscular AAV administration, characterized by expansion and cytotoxic potential, but poor capacity to be restimulated by the antigen and to eliminate transduced cells (56–58).”
Metadata
- Authors
- Lin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J.
- Affiliations
- The Wistar Institute (US)
- Corresponding author
- Ertl, Hildegund C.J.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-11-15
- Volume
- 117
- Issue
- 12
- Pages
- 3958-70
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2078325
- OpenAlex
- W2164754609
- Cited by
- 88
- References
- 75
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 3 · 2021: 2 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 7 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 6 · 2012: 5
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- U.S. Public Health Service (P01 A1055018-02)
- National Heart, Lung, and Blood Institute (P01HL078810)
- National Institute of Allergy and Infectious Diseases
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- recombinant adeno-associated virus vectors, HIV-1 Gag, CD8+ T cells, T cell proliferation, interferon-gamma, AAV serotypes, prime-boost vaccination, HIV-1 vaccine, antigen persistence, T cell dysfunction, vaccine immunogenicity
- MeSH terms
- Dependovirus, Adenoviridae, Animals, Genetic Vectors, Humans, Immunization, Secondary, Mice, Inbred BALB C, HIV-1, AIDS Vaccines, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Mice, gag Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.